Table 2.

TFAP2D immunostaining results and prostate cancer phenotype in all cancers, ERG negative cancers, and ERG positive cancers

	TFAP2D IHC result all cancers				TFAP2D IHC result in ERG negative cancers				TFAP2D IHC result in ERG positive cancers
	n 13545	negative (%) 24.3	positive (%) 75.7	p value	n 4722	negative (%) 33.2	positive (%) 66.8	p value	n 3776	negative (%) 11.3	positive (%) 88.7	p value
Tumor stage
pT2	8569	26.6	73.4	< 0.0001	3114	35.3	64.7	< 0.0001	2268	11.3	88.7	0.8159
pT3a	3054	21.9	78.1		982	32.4	67.6		998	10.8	89.2
pT3b-4	1866	17.1	82.9		612	23.2	76.8		495	11.9	88.1
Gleason grade
≤ 3 + 3	2391	31.8	68.2	< 0.0001	865	42.7	57.3	< 0.0001	725	14.3	85.7	0.0256
3 + 4	7246	24.7	75.3		2530	34	66		2203	10.9	89.1
3 + 4 Tert.5	648	22.8	77.2		216	29.6	70.4		117	11.1	88.9
4 + 3	1354	18.8	81.2		518	25.3	74.7		374	8.8	91.2
4 + 3 Tert.5	988	15.9	84.1		305	23.9	76.1		211	7.6	92.4
≥ 4 + 4	809	18.3	81.7		284	23.6	76.4		143	13.3	86.7
Gleason grade quant
3 + 4 ≤ 5%	1839	27.8	72.2	< 0.0001	673	37.7	62.3	< 0.0001	550	12.7	87.3	0.0636
3 + 4 6–10%	1811	25.1	74.9		663	34.5	65.5		582	10.3	89.7
3 + 4 11–20%	1609	23.8	76.2		574	34.3	65.7		488	9.4	90.6
3 + 4 21–30%	825	21.6	78.4		288	29.2	70.8		284	9.2	90.8
3 + 4 31–49%	682	22.1	77.9		256	30.9	69.1		209	12	88
4 + 3 50–60%	564	19.5	80.5		216	26.9	73.1		168	8.3	91.7
4 + 3 61–80%	495	17.6	82.4		206	23.8	76.2		143	7.7	92.3
4 + 3 > 80%	125	16	84		52	19.2	80.8		33	12.1	87.9
Lymph node metastasis
N0	8141	23.8	76.2	< 0.0001	2725	32.6	67.4	< 0.0001	2142	11.4	88.6	0.4192
N+	1032	15.6	84.4		285	20.7	79.3		242	13.2	86.8
Preop. PSA level (ng/ml)
< 4	1624	21.6	78.4	0.0101	487	30.4	69.6	0.2017	526	10.6	89.4	0.012
4–10	7988	24.2	75.8		2797	33.6	66.4		2332	10.2	89.8
10–20	2846	24.8	75.2		1033	31.8	68.2		661	14.1	85.9
> 20	1008	27.1	72.9		384	36.5	63.5		231	15.2	84.8
Surgical margin
negative	10,764	24.8	75.2	0.0045	3743	33.6	66.4	0.2278	2983	11.5	88.5	0.4099
positive	2732	22.2	77.8		967	31.5	68.5		777	10.4	89.6